Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBT Margin (2017 - 2025)

Crinetics Pharmaceuticals has reported EBT Margin over the past 9 years, most recently at 1990.5% for Q4 2025.

  • For Q4 2025, EBT Margin changed N/A year-over-year to 1990.5%; the TTM value through Dec 2025 reached 6041.5%, up 2260855.0%, while the annual FY2025 figure was 6043.88%, 2263158.0% up from the prior year.
  • EBT Margin for Q4 2025 was 1990.5% at Crinetics Pharmaceuticals, up from 90972.73% in the prior quarter.
  • Over five years, EBT Margin peaked at 1074.23% in Q1 2022 and troughed at 90972.73% in Q3 2025.
  • A 5-year average of 15155.36% and a median of 9400.75% in 2022 define the central range for EBT Margin.
  • On a YoY basis, EBT Margin climbed as much as 733895bps in 2025 and fell as far as -1640581bps in 2025.
  • Year by year, EBT Margin stood at 2857.88% in 2021, then plummeted by -125bps to 6438.93% in 2022, then plummeted by -153bps to 16302.89% in 2023, then dropped by -14bps to 18556.89% in 2024, then soared by 89bps to 1990.5% in 2025.
  • Business Quant data shows EBT Margin for CRNX at 1990.5% in Q4 2025, 90972.73% in Q3 2025, and 11217.94% in Q2 2025.